Correlation of Src activation with response to dasatinib, capecitabine, oxaliplatin, and bevacizumab in advanced solid tumors.
Year: 2013
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Duke Medical Center, Duke University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2595050331
